ARS Pharmaceuticals Inc SPRY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.81
- Day Range
- $9.57–9.91
- 52-Week Range
- $6.66–18.90
- Bid/Ask
- $9.70 / $9.87
- Shares Outstanding
- 99.30M
- Market Cap
- $963.24M
- Volume/Avg
- 3,804 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 159
- Website
- https://www.ars-pharma.com
Valuation
|
Metric
|
SPRY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 15.81 |
Price/Sales | 9.75 |
Price/Cash Flow | — |
Price/Earnings
SPRY
Financial Strength
|
Metric
|
SPRY
|
|---|---|
Quick Ratio | 4.63 |
Current Ratio | 4.94 |
Interest Coverage | — |
Quick Ratio
SPRY
Profitability
|
Metric
|
SPRY
|
|---|---|
Return on Assets (Normalized) | −53.34% |
Return on Equity (Normalized) | −116.69% |
Return on Invested Capital (Normalized) | −83.79% |
Return on Assets
SPRY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Gnbjyptv | Zxrbwj | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pzwxxrsc | Mlgqrz | $64B | |||
| argenx SE ADR
ARGX
| Rhwwzsmm | Ygrj | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Byqnzgjb | Dszzcjm | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Gdqyvkzv | Wcydy | $24B | |||
| BioNTech SE ADR
BNTX
| Hyvrpkd | Wzf | $23B | |||
| Incyte Corp
INCY
| Thjrkvg | Bkyh | $22B | |||
| Moderna Inc
MRNA
| Ydvdjhpg | Qdyp | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Fjdhybxy | Hztd | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Fktrxqss | Jvp | $13B |
United States